Phytocannabinoid medicine company, MGC Pharmaceuticals to list on LSE
LONDON: MGC Pharmaceuticals, a European based and Australian listed bio-pharma company, is in the final stages of listing the Company’s shares on the Standard Segment...
MGC Pharmaceuticals completes acquisition of Australian Medicinal Cannabis Clinics
SYDNEY: MGC Pharmaceuticals Ltd announced completion of the 100% acquisition of the operating telehealth clinic business assets, data and intellectual property of Medicinal Cannabis Clinics...
MGC Pharma receives cannabis cultivation research permit from Australian ODC
SYDNEY: MGC Pharmaceuticals (MXC), a European bio-pharma company specialising in the production and development of phytocannabinoid derived medicines, announced it has been granted a Cannabis...
MGC Pharma signs agreement for entry of cannabinoid medicines into new markets
PERTH: MGC Pharmaceuticals Ltd has signed a distribution agreement with Anden Bio Naturals S.A, a leading Peruvian medical products distributor, for the exclusive distribution and...
MGC launches new Cannabinoid products line in Australia & New Zealand
PERTH, AUSTRALIA: MGC Pharmaceuticals Ltd announced the launch of a new proprietary affordable prescription medicine line to be branded as Mercury Pharma, specifically for the...